UBS maintains a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target lowered from $60 to $52.

Analyst, Marc Goodman ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE